

SUPPLEMENTARY FIGURE AND TABLE

RAF1:

3 ' 637:5 '	uguuguuuuaguga UCAGAAGG u cccucucagggagcAGUCUUCCa	5' hsa-miR-7-5p 3' <i>RAF1</i> 3'UTR
3 ' 661:5 '	uguUGUUUUAGUGA UCAGAAGG u : : : cauGCUGAAU--UUUGUCUUCCa	5' hsa-miR-7-5p 3' <i>RAF1</i> 3'UTR

EGFR:

3 ' 441:5 '	ugUJGU-UUUAGUGA UCAGAAGG u : : ggAGCACACAAGCCACAAGUCUUCCa	5' hsa-miR-7-5p 3' <i>EGFR</i> 3'UTR
3 ' 725:5 '	ugUUGUUUUAGUGAU CAGAAGG u : : : uaGACUGACUUGUUUGUCUUCCa	5' hsa-miR-7-5p 3' <i>EGFR</i> 3'UTR

Schematic of two putative miR-7 seed binding sites in the *RAF1* and *EGFR* 3 UTR, respectively.

Supplementary Figure S1: Putative miR-7 seed binding sites in *RAF1* and *EGFR* 3'UTR.

Supplementary Table S1: Selected predicted targets for experimental validation

Target	Pathway
<i>MTOR</i>	<i>MTOR signalling</i>
<i>EIF4E</i>	<i>MTOR signalling</i>
<i>PIK3CD</i>	<i>MTOR signalling</i>
<i>RPS6KB1</i>	<i>MTOR signalling</i>
<i>RAF1</i>	<i>MAPK signalling</i>
<i>IGF1-R</i>	<i>Akt signalling</i>
<i>EGFR</i>	<i>MAPK signalling</i>
<i>IRS2</i>	<i>Insulin signalling</i>
<i>RB1</i>	<i>Cell Cycle signalling</i>
<i>SP1</i>	<i>TGF-Beta signalling</i>